NCT00694902 - Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2008

Primary Completion Date

September 23, 2008

Study Completion Date

September 23, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK610677

GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.

DRUG

Placebo

Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.

Trial Locations (1)

14050

GSK Investigational Site, Berlin